- Home
- NTLA vs TDUP Comparison
NTLA vs TDUP Comparison
Compare NTLA & TDUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- TDUP
- Stock Information
- Founded
- NTLA 2014
- TDUP 2009
- Country
- NTLA United States
- TDUP United States
- Employees
- NTLA N/A
- TDUP N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TDUP Catalog/Specialty Distribution
- Sector
- NTLA Health Care
- TDUP Consumer Discretionary
- Exchange
- NTLA Nasdaq
- TDUP Nasdaq
- Market Cap
- NTLA 1.2B
- TDUP 1.3B
- IPO Year
- NTLA 2016
- TDUP 2021
- Fundamental
- Price
- NTLA $12.27
- TDUP $8.62
- Analyst Decision
- NTLA Buy
- TDUP Buy
- Analyst Count
- NTLA 20
- TDUP 3
- Target Price
- NTLA $25.83
- TDUP $12.50
- AVG Volume (30 Days)
- NTLA 9.7M
- TDUP 1.3M
- Earning Date
- NTLA 11-06-2025
- TDUP 11-03-2025
- Dividend Yield
- NTLA N/A
- TDUP N/A
- EPS Growth
- NTLA N/A
- TDUP N/A
- EPS
- NTLA N/A
- TDUP N/A
- Revenue
- NTLA $52,857,000.00
- TDUP $277,729,000.00
- Revenue This Year
- NTLA $9.20
- TDUP $18.12
- Revenue Next Year
- NTLA N/A
- TDUP $9.55
- P/E Ratio
- NTLA N/A
- TDUP N/A
- Revenue Growth
- NTLA 14.99
- TDUP 20.14
- 52 Week Low
- NTLA $5.90
- TDUP $0.50
- 52 Week High
- NTLA $28.25
- TDUP $12.28
- Technical
- Relative Strength Index (RSI)
- NTLA 32.04
- TDUP 41.40
- Support Level
- NTLA $13.21
- TDUP $8.78
- Resistance Level
- NTLA $26.35
- TDUP $9.45
- Average True Range (ATR)
- NTLA 1.91
- TDUP 0.41
- MACD
- NTLA -1.94
- TDUP 0.02
- Stochastic Oscillator
- NTLA 3.07
- TDUP 7.25
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.